Systemic lupus erythematosus (SLE) is a nonorgan-speci®c autoimmune disorder associated with B cell hyperactivity and, thereby, with a plethora of autoantibodies. T cell help is, however, required for the production of pathogenic antibodies. 1 It has also become increasingly clear, over the past few years, that cytokines contribute markedly to the pathogenesis of such a condition. 2 There has, therefore, been intense interest in trying to control their effects in the design of new treatments for the disease. 3 In this respect, the transforming growth factor beta (TGF-b) family of proteins are now suspected to be pivotal cytokines in the activation of B cells, 4 especially as several effects of TGF-b are being unraveled with the bene®t of new data.
There are at least three isoforms of TGF-b, namely, TGF-b 1, 2 and 3 which are produced by every hematopoietic cell lineage, including dendritic cells, macrophages, lymphocytes and NK cells. 5 Although a number of different experimental systems have produced con¯icting results regarding the in¯uence of TGF-b on T helper (Th) differentiation, the production of this cytokine by antigen-speci®c T cells may de®ne a unique Th subset, referred to as TGF-b -producing Th cells or Th 3. 6 One further concern with TGF-b is that the protein is secreted as a latent precursor and converted to its active form extracellularly. 7 Several mechanisms have been described. 4, 7 Latent TGF-b may bind to thrombospondin 1 (once this peptide has been inserted into its receptor) and, thereby, differentiate into its active form following the action of membrane-bound plasmin. Curiously enough, B cell-induced TGF-b may also link to IgG autoantibodies and the resulting complex be captured by high-af®nity Fc-g receptors on the surface of macrophages, and converted to the mature form. Noteworthy is that 80% of the IgG-complexed TGF-b are biologically active.
This ®nding is dif®cult to reconcile with the recent report that lymphocyte production in both the total and biologically active form TGB-b is reduced in SLE, 8 inasmuch as this cytokine suppresses th such as diabetes, collagen-induced arthritis or experimental autoimmune encephalomyelitis (EAE). Interleukin (IL)-4 and TGF-b-producing cells accumulate in the target organ during recovery following an acute episode 9 and, in EAE, relapses can be prevented by TNF-b administration and IL-10. 10 Interestingly, an inhibitory circuit involving nanomolar concentrations of TGF-b can suppress T or B cell function, 5 whereas lower concentrations may be used to generate regulatory T cells. 11 In this issue, Ohtsuka et al 12 reported a convincing demonstration that NK cell-induced TGF-b costimulates IL-2-activated CD8-positive T cells, which results in a down-regulation of autoantibody production in SLE. It is of considerable interest that this down-regulation of IgG by IL-2 can be either TGF-b-dependent or independent in individual patients.
Furthermore, decreased production of active TGF-b in patients with SLE does not correlate with disease activity or severity, 13 indicating that activation of this cytokine may result from one of the several mechanisms described above which might be due to inherited abnormalities. This interpretation is perfectly in line with the fact that NK cells are the only lymphocyte population to constitutively produce TGF-b in its active form, 5 because constitutive production of NK cell-derived TGF-b is diminished in SLE. In contrast, the reduction of total TGF-b in the same patients appears to correlate with disease activity, to result as its consequence and to re¯ect the presence of severe complications of SLE.
These interesting studies yield new informations and provide a framework to support a model in which TGF-b is of the utmost importance in the regulation of autoimmunity. This is such a multifunctional family of cytokines that paradoxical effects are likely to be described, particularly in SLE.
